maravai lifesciences holdings glp-1 receptor agonist medications Harnessing Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon GLP-1 Pipeline Update: February 2025

Key mechanisms of action include: Appetite suppression through central nervous system pathways that regulate hunger and satiety Delayed gastric emptying , which prolongs the sensation of fullness after eating Improved glucose metabolism and insulin sensitivity, which may benefit individuals with obesity-related metabolic complications GIP receptor antagonism , which may influence fat metabolism and energy storage The once-monthly dosing schedule is achieved through the extended half-life of the antibodypeptide construct, which may improve convenience and adherence compared with current weekly injectable obesity treatments

Natures GLP-1

The promising obesity outcomes enabled by drugs such as Wegovy have prompted other drug manufacturers to pursue their own development efforts to help claim their share of this unprecedented market opportunity

Some people taking GLP-1 medications may experience digestive side effects, with these being the most common: Nausea, especially at the start or after a dose increase Heartburn or stomach discomfort after meals Constipation, which can occur as the body adjusts Diarrhea, which may be mild or bothersome Vomiting, sometimes along with nausea Most digestive side effects lessen as the body adjusts

"Trump administration in talks with Novo Nordisk, Eli Lilly on GLP-1 drug pricing"

Curr Opin Obstet Gynecol 29(3):180187 Marshall NE, Abrams B, Barbour LA et al (2022) The importance of nutrition in pregnancy and lactation: lifelong consequences